IPC Research

Waukesha, Wisconsin 53188

0 studies enrolling now · 8 studies all time

What they study most

Adjunctive Treatment of Major Depressive Disorder, Agitation in Participants With Dementia of the Alzheimer's Type, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease

Studies at this site

• Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type — Completed
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Stopped early
• Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Completed
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) — Completed
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease — Completed
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed